Drug intelligence / Profile preview

VXN-MHYO

Development stage: Unknown
Lead developer: Vaxinano
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral, Intranasal

Overview

VXN-MHYO is a veterinary nanoparticle vaccine developed by Vaxinano for the prevention of *Mycoplasma hyopneumoniae* infections in swine, the causative agent of enzootic pneumonia. The vaccine utilizes Vaxinano's proprietary STELLAR-NP technology to formulate inactivated *Mycoplasma hyopneumoniae* pathogens into nanoparticles, which enhances the induction of protective immunity. VXN-MHYO is being developed as a monovalent vaccine, currently in Phase 3 clinical trials, and is also being evaluated in preclinical studies as part of a combined vaccine formulation.

Beyond the preview

Go deeper on VXN-MHYO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXN-MHYO.

Explore the full profile